A/Pr Trent Woodruff
University of Queensland
Complement activation as a therapeutic target and clinical biomarker for Parkinson's disease
National Health and Medical Research Council
Parkinsons disease is the second most common neurological disease in Australia, yet there is no treatment to slow disease progression. Our study is investigating inflammation within the brain as a major contributing factor in Parkinsons disease. We will examine this inflammatory pathway in human patients suffering from Parkinsons, and will test a novel anti-inflammatory drug in animal models of Parkinsons disease, in order to identify a novel treatment to reduce disease pathology.